Final analysis of Chromogranin A for neuroendocrine tumor diagnosis in Chilean patients: An updated case-control study

#3557

Introduction: Neuroendocrine tumors (NETs) are highly heterogeneous and differ geographically. Serum chromogranin A (CgA) is the most used biomarker for NET diagnosis, with a sensitivity of 63-100% and specificity of 95-98% with a cutoff value of 108 ng/mL. Recent studies worldwide have reported varying frequencies of NET patients with high CGA at diagnosis, suggesting that the cutoff value may differ according to each population.

Aim(s): To assess serum CgA levels in Chilean healthy subjects and NET patients.

Materials and methods: 76 NET patients and 70 healthy subjects were prospectively recruited. Serum CgA levels were measured by ELISA. The Wilcoxon-Mann-Whitney U test was used for the comparison of tumor-marker distribution in the study populations. To determine cut-off value, sensitivity, and specificity, the area under the curve (AUC) was calculated on receiver operating characteristic (ROC) curve analysis. Summary threshold measures were determined by Youden Index.

Conference:

Presenting Author: Muñoz Medel M

Authors: Muñoz Medel M, Cordova Delgado M, Duran D, Pinto M, Bravo M,

Keywords: neuroendocrine, chromogranin a, biomarker,